Akebia Therapeutics (AKBA) Current Deferred Revenue (2016 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Current Deferred Revenue of $4.5 million for Q1 2026, up 262.29% year-over-year from $1.2 million in Q1 2025, and up 67.7% quarter-over-quarter from $2.7 million in Q4 2025.
Akebia Therapeutics (AKBA) Current Deferred Revenue (2016 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Current Deferred Revenue for 11 consecutive years, with $4.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 262.29% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (up 262.29% YoY), while the FY2025 annual figure was $2.7 million, changed N/A from the prior year.
- Current Deferred Revenue rose to $4.5 million in Q1 2026 per AKBA's latest filing, from $2.7 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $66.3 million in Q3 2022 and bottomed at $1.2 million in Q1 2025.
- Historically, Current Deferred Revenue has averaged $30.5 million across 5 years, with a median of $43.3 million in 2023.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue sank 97.18% — and 2026, when it surged 262.29%.
- Akebia Therapeutics' Current Deferred Revenue stood at $47.0 million in 2022, then slipped by 7.95% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024, then plunged by 93.81% to $2.7 million in 2025, then jumped by 67.7% to $4.5 million in 2026.
- Business Quant data shows AKBA's Current Deferred Revenue at $4.5 million in Q1 2026, $2.7 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.17 Mn |
| Mar 31, 2026 | 4.50 Mn |
| Dec 31, 2025 | 2.68 Mn |
| Sep 30, 2025 | 3.88 Mn |
| Jun 30, 2025 | 5.53 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Jun 30, 2024 | 43.30 Mn |
| Mar 31, 2024 | 43.99 Mn |
| Dec 31, 2023 | 43.30 Mn |
| Sep 30, 2023 | 43.30 Mn |
| Jun 30, 2023 | 43.30 Mn |
| Dec 31, 2022 | 47.03 Mn |
| Sep 30, 2022 | 66.31 Mn |
| Jun 30, 2022 | 48.34 Mn |
| Dec 31, 2021 | 42.38 Mn |
| Sep 30, 2021 | 43.66 Mn |
| Dec 31, 2020 | 10.00 Mn |
| Sep 30, 2020 | 51.69 Mn |
| Jun 30, 2020 | 615,000.00 |
| Mar 31, 2020 | 77.69 Mn |